Moxonidina en hipertensión arterial resistente a politerapia antihipertensiva

Banegas, 2004, Blood pressure control and physician management of hypertension in hospital hypertension units in Spain, Hypertension, 43, 1338, 10.1161/01.HYP.0000127424.59774.84 Robles, 2000, Agentes centrales en hipertensión arterial: Regreso al futuro, Nefrología, 20, 302 Enrsberger, 1997, The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease, J. Hypertens, 15, S9, 10.1097/00004872-199715011-00002 Enrsberger, 1992, A second generation of centrally acting antihypertensive agents act on putative I1-imidazoline receptor, J Cardiovasc Pharmacol, 20, S1, 10.1097/00005344-199220004-00002 Buccafusco, 1995, Role of medullary I1-imidazoline and a2-adrenergic receptors in the antihypertensive responses evoked by central administration of clonidine analogs in concious spontaneously hypertensive rats, J. Pharmacol Exp Ther, 273, 1162 Enrsberger, 1993, Moxonidine, a centrally-acting antihypertensive agent, is a selective ligand for I1-imidazoline sites, J Pharmacol Exp Ther, 264, 172 Enrsberger, 1995, I1-imidazoline receptors: definition, charaterization, distribution and transmembrane signalling, Ann NY Acad Sci, 763, 22, 10.1111/j.1749-6632.1995.tb32388.x Staessen, 2000, Risk of untreated and treated isolated systolic hypertension in the elderly, Lancet, 355, 865, 10.1016/S0140-6736(99)07330-4 Prichard, 1996, Effective antihypertensive therapy: blood pressure control with moxonidine, J Cardiovasc Pharmacol, 27, S38, 10.1097/00005344-199627003-00006 Crisp, 1992, Moxonidine, Drugs, 44, 993, 10.2165/00003495-199244060-00008 N’Guyen van Cao, 1988, Non-invasive study of cardiac structure and function after rilmenidine for essential hypertension, Am J Cardiol, 61, 72D, 10.1016/0002-9149(88)90469-9 Mitrovic, 1991, Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension, Cardiovasc Drug Ther, 5, 967, 10.1007/BF00143521 Rupp, 1994, Mechanisms of cardiac cell damage due to cathecolamines: significance of drugs regulating central sympathetic outflow, J Cardiovasc Pharmacol, 24, 16, 10.1097/00005344-199424001-00004 Ziegler, 1988, ZNS-Effeckte von Moxonidin einem neuem zentralnervos wirkender Antihypertensivum, in vergleich zu Clonidin und Placebo, Klin Wochenschr, 66, 41 Schmidt, 1992, Hypertension: a possible risk in road traffic, J Cardiovasc Pharmacol, 20, S50, 10.1097/00005344-199220004-00011 Thoolen, 1981, Discontinuation syndrome after continuous infusion of clonidine in the spontaneously hypertensive rat, Life Sci, 28, 2103, 10.1016/0024-3205(81)90616-0 Plänitz, 1984, Crossover comparison of moxonidine and clonidine in mild to moderate hypertension, Eur J Clin Pharmacol, 27, 147, 10.1007/BF00544037 Schachter, 1998, Safety and tolerability of moxonidine in the treatment of hypertension, Drug Safety, 19, 191, 10.2165/00002018-199819030-00003 Enrsberger, 1996, Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholitic agent, Cardiovasc Drugs Ther, 10, 275, 10.1007/BF00120497 Enrsberger, 1994, Refeeding hypertension in obese SHR, Hypertension, 24, 699, 10.1161/01.HYP.24.6.699 Tsoli, 1995, The imidazoline I1 receptor agonist, moxonidine, inhibits insulin secretion from isolated rat islets of Langerhans, Eur J Pharmacol, 284, 199, 10.1016/0014-2999(95)00455-T Kaan, 1995, Effects of agmatine and moxonidine on glucose metabolism: an integrated approach towards pathophysiological mechanism in cardiovascular metabolic disorders, Cardiovasc Risk Factors, 5, 19 Almazov, 2000, Insulin resistance and arterial hypertension. The influence of moxonidine and metformin therapy. [Abstract], J Hypertens, 18, S12, 10.1097/00004872-200006001-00022